This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kern, W. Articles by Schleyer, E. Search for Related Content PubMed PubMed Citation Articles by Kern, W. Articles by Schleyer, E.

Oxaliplatin Pharmacokinetics during a Four-Hour Infusion

Ludwig-Maximilians-University, University Hospital Grosshadern, Department of Medicine III, 81366 München [W. K., J. B., W. H.]; and Georg-August-University, Department of Hematology and Oncology, 37075 Göttingen [B. B., C. C. K., E. S.], Germany

A new platin compound, oxaliplatin, has significant activity in advanced colorectal carcinomas. However, its pharmacokinetics have not been characterized adequately yet. This study extensively analyzes the pharmacokinetics of both ultrafiltrable (free) and protein-bound platin in 13 patients receiving 130 mg/m² oxaliplatin as a 4-h infusion in combination with 375 mg/m² 5-fluorouracil as a 24-h infusion for advanced colorectal carcinomas. The interpatient variability was very low for all parameters analyzed. The levels of free platin decreased triphasically, with a mean terminal half-life of 27.3 ± 10.6 h. The area under the time-concentration curve was 20.17 ± 6.97 µg·h/ml and the total and renal clearances amounted to 222 ± 65 and 121 ± 56 ml/min, respectively. The values for the volume of distribution and for the maximum concentration at the end of infusion were 349 ± 132 liters and 1612 ± 553 ng/ml, respectively. On the basis of the simulation of the plasma levels and the urinary excretion of platin following the long-term administration of oxaliplatin as a constant-rate and a chronomodulated infusion, additional analyses are warranted to fully characterize the pharmacokinetics of the drug in these settings.

This article has been cited by other articles:

				J. Peng, R. Mandal, M. Sawyer, and X.-F. Li Characterization of Intact Hemoglobin and Oxaliplatin Interaction by Nanoelectrospray Ionization Tandem Mass Spectrometry Clin. Chem., December 1, 2005; 51(12): 2274 - 2281. [Abstract] [Full Text] [PDF]

				R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178. [Abstract] [Full Text] [PDF]

				D. Mavroudis, P. Pappas, C. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors Ann. Onc., February 1, 2003; 14(2): 304 - 312. [Abstract] [Full Text] [PDF]

				A. Falcone, G. Masi, G. Allegrini, R. Danesi, E. Pfanner, I. M. Brunetti, A. Di Paolo, S. Cupini, M. Del Tacca, and P. Conte Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., October 1, 2002; 20(19): 4006 - 4014. [Abstract] [Full Text] [PDF]

				M. A. Graham, G. F. Lockwood, D. Greenslade, S. Brienza, M. Bayssas, and E. Gamelin Clinical Pharmacokinetics of Oxaliplatin: A Critical Review Clin. Cancer Res., April 1, 2000; 6(4): 1205 - 1218. [Abstract] [Full Text]